Document Detail

Patient preference for latent tuberculosis infection preventive treatment: a discrete choice experiment.
MedLine Citation:
PMID:  21914516     Owner:  NLM     Status:  In-Data-Review    
OBJECTIVES: To quantify patient preferences when making decisions as to whether to accept latent tuberculosis infection (LTBI) preventive treatment, using a discrete choice experiment (DCE).
METHODS: A DCE survey was developed and administered to LTBI patients. Each patient was given 10 random choices along with two fixed choices to check consistency. Two hypothetical treatment options and one opt-out option were presented in each choice task. Latent class analysis was conducted to estimate preferences for six key treatment attributes.
RESULTS: Among the 214 respondents, 194 (90.7%) who provided valid DCE responses and complete sociodemographic information were included. Results consistently suggested that respondents were averse to higher risk of active tuberculosis and side effects and longer treatment. A three-latent-class model with five covariates was chosen. Forty-seven percent of the respondents were assigned to class 1, 32% to class 2, and 21% to class 3. Although all six attributes were shown to significantly influence the respondents' treatment decision, the risk of active tuberculosis, chance of liver damage, and frequency of clinic visits were the most important ones. Significant preference heterogeneity was observed in two attributes: frequency of clinic visits (P < 0.01) and chance of liver damage developing (P < 0.01). Class 1 individuals were most likely to have children. Class 2 had the highest employment rate. Class 3 respondents tended to choose the opt-out option on DCE tasks and were more likely to be born outside Canada, have higher education, and be unemployed.
CONCLUSION: Respondents consistently preferred preventive treatment with higher effectiveness, fewer side effects, and shorter length. Substantial preference heterogeneity existed among respondents.
Na Guo; Carlo A Marra; J Mark Fitzgerald; R Kevin Elwood; Aslam H Anis; Fawziah Marra
Related Documents :
23273526 - Relation of b-type natriuretic peptide level in heart failure to sudden cardiac death i...
19927266 - Bevacizumab in central retinal vein occlusion: a retrospective analysis after 2 years o...
24583096 - Early and long-term results after reconstructive surgery in 42 children and two young a...
16815246 - Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the t...
21050776 - Outcomes using a 1470-nm laser for symptomatic varicose veins.
22036146 - Allograft cellular bone matrix as an alternative to autograft in hindfoot and ankle fus...
Publication Detail:
Type:  Journal Article     Date:  2011-07-29
Journal Detail:
Title:  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research     Volume:  14     ISSN:  1524-4733     ISO Abbreviation:  Value Health     Publication Date:    2011 Sep-Oct
Date Detail:
Created Date:  2011-09-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883818     Medline TA:  Value Health     Country:  United States    
Other Details:
Languages:  eng     Pagination:  937-43     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.
Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Time Trade-Off Derived EQ-5D Weights for Australia.
Next Document:  Patient access to new cancer drugs in the United States and Australia.